Celebrating 79 years as a leader in the pharmaceutical industry, Serbian company Galenika has reported impressive growth in both product portfolio and international reach

In the first seven months of this year, the company registered 90 new products in Serbia and neighbouring markets, boosting overall production by 18% compared to the same period last year. Sales in Serbia have also risen by 18%, while the company’s presence in the EU more than doubled. 

Currently operating in 25 international markets, Galenika plans further expansion into 10 additional European and MENA region markets. The company’s strong performance is backed by its 40 leading brands in Serbia and a fruitful partnership with Brazil’s largest pharmaceutical firm, EMS.